Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function

被引：18

作者：

Li, Zhuzhu ^{[1
]}

Agharkar, Priyanka ^{[1
]}

Chen, Bin ^{[1
]}

机构：

[1] Univ Sci, Philadelphia Coll Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA

来源：

CANCER LETTERS | 2013年 / 339卷 / 01期

关键词：

Vascular-targeted photodynamic therapy (vPDT); Verteporfin; Reactive oxygen species (ROS); Bortezomib; Ubiquitination; Apoptosis; Combination therapy; ENDOPLASMIC-RETICULUM STRESS; MOUSE-TUMOR MODEL; FACTOR-KAPPA-B; INDUCED APOPTOSIS; OXIDATIVE STRESS; IN-VITRO; CANCER; CELLS; EXPRESSION; VERTEPORFIN;

D O I：

10.1016/j.canlet.2013.07.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular-targeted photodynamic therapy (vPDT) is a novel vascular targeting modality based on site-directed delivery of a photosensitizer to tumor vasculature, which induces reactive oxygen species (ROS)-mediated vascular effects upon light activation. To enhance the therapeutic outcome of vPDT, we combined proteasomal inhibitor bortezomib and vPDT using photosensitizer verteporfin in the present study. We found that bortezomib in combination with verteporfin-PDT induced more accumulation of ubiquitinated proteins and apoptosis in endothelial cells than each individual treatment. The combination therapy also enhanced vPDT-induced inhibition in tumor growth. These results indicate that bortezomib can be used together with verteporfin-PDT for enhanced treatment outcome. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：128 / 134

页数：7

共 39 条

[1] The development of proteasome inhibitors as anticancer drugs [J].

Adams, J .

CANCER CELL, 2004, 5 (05) :417-421

[2] Photodynamic Therapy of Cancer: An Update [J].

Agostinis, Patrizia ;

Berg, Kristian ;

Cengel, Keith A. ;

Foster, Thomas H. ;

Girotti, Albert W. ;

Gollnick, Sandra O. ;

Hahn, Stephen M. ;

Hamblin, Michael R. ;

Juzeniene, Asta ;

Kessel, David ;

Korbelik, Mladen ;

Moan, Johan ;

Mroz, Pawel ;

Nowis, Dominika ;

Piette, Jacques ;

Wilson, Brian C. ;

Golab, Jakub .

CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) :250-281

[3]

Belzacq AS, 2001, CANCER RES, V61, P1260

[4]

Brown S B, 2001, Expert Opin Pharmacother, V2, P351

[5] The present and future role of photodynamic therapy in cancer treatment [J].

Brown, SB ;

Brown, EA ;

Walker, I .

LANCET ONCOLOGY, 2004, 5 (08) :497-508

[6] Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment [J].

Byrne, A. T. ;

O'Connor, A. E. ;

Hall, M. ;

Murtagh, J. ;

O'Neill, K. ;

Curran, K. M. ;

Mongrain, K. ;

Rousseau, J. A. ;

Lecomte, R. ;

McGee, S. ;

Callanan, J. J. ;

O'Shea, D. F. ;

Gallagher, W. M. .

BRITISH JOURNAL OF CANCER, 2009, 101 (09) :1565-1573

[7] Tumor vascular permeabilization by vascular-targeting photosensitization: Effects, mechanism, and therapeutic implications [J].

Chen, B ;

Pogue, BW ;

Luna, JM ;

Hardman, RL ;

Hoopes, PJ ;

Hasan, T .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :917-923

[8] Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy [J].

Chen, B ;

Pogue, BW ;

Hoopes, PJ ;

Hasan, T .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (04) :1216-1226

[9]

Chen B, 2005, CLIN CANCER RES, V11, P720

[10] Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model [J].

Chen, B ;

Roskams, T ;

Xu, Y ;

Agostinis, P ;

de Witte, PAM .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :284-290

← 1 2 3 4 →